Skip to main content

Table 3 Simple Cox analysis indicating risk factors for P. aeruginosa respiratory infection and/or colonization

From: Oral probiotic and prevention of Pseudomonas aeruginosa infections: a randomized, double-blind, placebo-controlled pilot study in intensive care unit patients

Variable n P. aeruginosa (n [%]) Hazard ratio 95% CI P
Female sex 62 4 (6.5%) 0.71 0.23–2.15 0.54
Absence of probiotic 106 13 (12.3%) 3.31 1.17–9.40 0.024
Hospitalization duration < 15 days 107 4 (3.7%) 0.59 0.15–2.34 0.45
SAPS II score < 43 105 6 (5.7%) 0.69 0.26–1.85 0.46
Traumatology and surgical pathology 126 11 (8.7%) 0.97 0.38–2.51 0.95
Underlying respiratory tract disease 33 5 (15.2%) 1.63 0.58–4.58 0.35
Amoxicillin/clavulanate 120 13 (10.8%) 0.41 0.14–1.20 0.10
Piperacillin + tazobactam 21 3 (14.3%) 1.24 0.36–4.33 0.73
Cefotaxime 54 7 (13.0%) 1.15 0.44–3.01 0.77
Cefepime 42 6 (14.3%) 1.03 0.38–2.80 0.96
Ceftazidime 33 7 (21.2%) 1.59 0.59–4.27 0.35
Imipenem 30 6 (20.0%) 1.05 0.36–3.03 0.93
Aminoglycosides 20 1 (5.0%) 0.28 0.04–2.14 0.22
Ciprofloxacin 74 8 (10.8%) 0.59 0.22–1.59 0.30
Quinolones 138 14 (10.1%) 0.66 0.21–2.09 0.48
Glycopeptides 59 10 (16.9%) 1.42 0.54–3.76 0.47
Fluconazole 71 8 (11.3%) 0.56 0.21–1.50 0.25
Enterobacteriaceae infection/colonization 91 9 (9.9%) 0.88 0.35–2.24 0.79
Candida respiratory tract colonization 20 2 (10.0%) 0.60 0.13–2.65 0.50
S. aureus respiratory tract infection/colonization 39 8 (20.5%) 1.69 0.65–4.39 0.28
  1. CI, confidence interval; SAPS, Simplified Acute Physiology Score.